Contact
SYNICEM™ HIP SPACER

Preformed, antibiotic loaded hip spacer to maintain space and aid treatment of infection

Specifically designed to support your management of infection in hip revision

Combining convenience, structural uniformity and stability, whilst delivering a high local concentration of gentamicin.
SYNICEM™ HIP SPACERS maintain joint space and limb length to preserve the abduction and stabilisation structure of the hip.6

  • Precision engineered for consistency and structural uniformity
  • Designed for dynamic movement and stability
  • Preloaded with gentamicin to aid treatment of infection
  • Case-by-case flexibility and time-saving

Precision engineered for consistency and structural uniformity

Strictly controlled manufacturing conditions minimise the risk of mechanical failure by eliminating unwanted variation in the shape
and structural integrity of the base material.

  • Perfectly spherical and polished finish of the femoral head prevents bone stock wear6
  • Lower complication rates and risk of periprosthetic fracture compared to intra-operatively prepared spacers1

Designed for dynamic movement and stability

Designed to maintain joint space and limb length to preserve the abduction and stabilisation structure after removal of the original implant.6

  • Choice of Charnley and Müller spacer design
  • Uniform stainless-steel core to increase mechanical resistance

Preloaded with gentamicin to aid treatment of infection

The spacer yields a high local concentration of gentamicin while maintaining low systemic levels to aid the treatment of infection.6

Case-by-case flexibility and time-saving

A comprehensive range of sizes and styles provide case-by-case flexibility, with a reusable spacer tray available to ensure you select the correct size every time.6

  • No moulding required

SYNICEM™ HIP SPACER products
SYNICEM™ KNEE SPACER

Specifically designed to support your management of infection in knee revision

SYNICEM™ SHOULDER SPACER

Specifically designed to support your management of infection in shoulder revision

References and regulatory statements

1. Craig, A., King, S.W., van Duren, B.H., Veysi, V.T., Jain, S., & Palan, J. (2022). Articular spacers in two-stage revision arthroplasty for prosthetic joint infection of the hip and the knee. EFORT Open Reviews, 7, 137 – 152.
2. D’Angelo, Fabio, L. Negri, Giovanni Zatti and F. A. Grassi. “Two-stage revision surgery to treat an infected hip implant. A comparison between a custom-made spacer and a pre-formed one.” La Chirurgia degli organi di movimento 90 3 (2005): 271-9.
3. Dunne, N., Hill, J., McAfee, P., Todd, K., Kirkpatrick, R., Tunney, M., & Patrick, S. (2007). In vitro study of the efficacy of acrylic bone cement loaded with supplementary amounts of gentamicin: effect on mechanical properties, antibiotic release, and biofilm formation. Acta orthopaedica, 78(6), 774–785.
4. Quanjun Cui; William M Mihalko; “Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty”. The Journal of Bone and Joint Surgery. American Volume. 89(4):871-82, APR 2007.
5. Moerenhout, K., Steinmetz, S., Vautrin, M., Picarra, S., Udin, G., & Borens, O. (2021). Economic advantage of ‘self-made’ antibiotic-loaded spacer compared to prefabricated antibiotic-loaded spacer and spacer molds in two-staged revision arthroplasty. Acta orthopaedica Belgica, 87(3), 557–562.
6. Synimed, Synicem Instruction for Use.

For indications, contraindications, warnings and precautions see Instructions for Use. Concurrent use of locally administered antibiotics may affect setting time, absorption characteristics and/or bone formation. It is the surgeon/healthcare professional’s responsibility to give due consideration to the details in the medicinal product marketing authorization in deciding whether it is appropriate for the patient under his/her care. The relevant Summary of Product Characteristics (SmPC) must be consulted. The type and dose of medicinal substance should also be assessed according to the individual patient’s clinical circumstance.
This brochure may include the use of STIMULAN or techniques that go beyond the current clearance / approval granted by the relevant regulatory authority. Please contact your local representative for further information.

©2024, Biocomposites, STIMULAN are trademarks/registered trademarks of Biocomposites Ltd. Synimed and Synicem are trademarks/registered trademarks of Synergie Ingénierie Médicale S.A.R.L. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.

Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 8883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1, US 10390954, US 10,588,748,CN ZL201610089710.5
Patents pending: GB1502655.2, GB1704688.9, EP 18275044.8, US 15/933936, CN 108619579A

MA0416R2